NeoGenomics (NEO) Reports In-Line Q4 EPS, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
NeoGenomics Reports 40% Revenue Growth to $107 Million in the Fourth Quarter
February 27, 2020 7:10 AM ESTFourth-Quarter 2019 Highlights:
Consolidated revenue increased 39.7% to $106.9 millionClinical Services revenue increased 41.7% to $93.4 million Pharma Services revenue increased 27.5% to $13.5 millionPharma Services backlog increased 31.8% to $130.3 millionCompany issues 2020 financial guidanceFT. MYERS, FL / ACCESSWIRE / February 27, 2020 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced fourth-quarter and full-year 2019 results for the period ended December 31, 2019.
"Our fourth quarter performance concludes a very successful year for NeoGenomics in which our company grew by nearly 50%... More
